CAR-T Consortium

The Chimeric Antigen Receptor T-Cell (CAR-T) Consortium unites investigators from scientific and medical associations, government agencies, and registries, to address emerging toxicities associated with the application of CAR-T therapies. The consortium is expected to convene on a bimonthly basis (i.e., every other month), with its first order of business being to conduct a landscape analysis of the field. Based on its assessment, it will then ascertain and develop resources to address important gaps.

Goals and Objectives

The consortium, consisting of representatives from scientific and medical associations, the U.S. Food and Drug Administration, and the Center for International Blood and Marrow Transplant Research working together, will address urgent needs related to emerging CAR-T adverse events and identify opportunities to address the following areas:

  1. Increasing investigators’ understanding of the molecular mechanisms surrounding these toxicities and the role conditioning regimens could play in their onset.  
  2. Exploring ways to effectively report and catalog these toxicities to inform future research.  
  3. Developing educational resources for clinicians to inform toxicity management approaches.  
  4. Informing regulatory agencies on the challenges and recent developments in the field surrounding this topic.

Questions?

For more information on the CAR-T Toxicities Consortium, please contact ASH Director of Scientific Affairs, Alice Kuaban, MS at akuaban@hematology.org. 

Consortium Members

Members consist of individuals who have expertise in CAR T cells and the ability to carry forward recommendations from this consortium to their respective organizations.

American Society of Hematology (ASH)

  • Nirali N. Shah, MD (Chairperson)
  • Robert Negrin, MD (Vice Chairperson)
  • Alice Kuaban, MS (Staff Liason)

American Association for Cancer Research (AACR)

  • Helen E. Heslop, MD (Representative) (Hon)
  • Nikhil C. Munshi, MD (Representative)

American College of Rheumatology (ACR)

  • Maximilian F. Konig, MD (Representative) (Hon)
  • C. Thomas Appleton, MD, PhD, FRCPC (Representative)

ASH Research Collaborative (ASH RC)

  • Saad Zafar Usmani, MD, MBA (Representative)
  • William A. Wood Jr., MD, MPH (Representative)

American Society of Gene & Cell Therapy (ASGCT)

  • Isabelle Riviere, PhD (Representative)
  • Marco Davila, MD, PhD (Representative)

American Society for Transplantation and Cellular Therapy (ASTCT)

  • Frederick Locke, MD (Representative)
  • Marcela V. Maus, MD (Representative)

Center for International Blood and Marrow Transplant Research (CIBMTR)

  • Amy Moskop, MD, MS (Representative)

International Society For Cell & Gene Therapy (ISCT)

  • Jaap Jan Boelens, MD (Representative)
  • Bruce Levine, PhD (Representative)

U.S. Food and Drug Administration (FDA)

  • Megha Kaushal, MD, MSc (Representative)

Society for Immunotherapy of Cancer (SITC)

  • Adam Schoenfeld, MD (Representative)
  • Kristen Hege, MD (Representative)